This innovative affibody construct was specifically designed to bind two distinct, non-overlapping epitopes on VEGFR-2, a strategy that significantly enhanced binding affinity, specificity, and tumor retention compared with traditional monovalent constructs. The gene discussed is KDR; the disease is neoplasm.